Thursday, July 30, 2015
Avista Pharma Solutions has acquired the GMP contract manufacturing, development and animal health services business of Scynexis. Avista will occupy Scynexis’ former research and GMP manufacturing facility in Durham, N.C., and hire substantially all employees associated with the contract services business.
Global CRO Parexel International launched the next generation of its Perceptive MyTrials platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors now can use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. The solution offers real-time and aggregated analytics allowing sponsors and Parexel clinical research professionals to detect key signals and trends. The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.
Evans Analytical Group (EAG), a fully integrated, independent laboratory network based in Boston, has acquired Analytical Bio-Chemistry Laboratories, of Columbia, Mo. (ABC Laboratories). EAG is a private company, majority owned by Odyssey Investment Partners. Financial terms of the transaction have not been disclosed.
Covance Drug Development has relocated its clinical research unit (CRU) in Dallas to a new, fit-for-purpose clinical research facility. The new unit, which opened earlier this month, has expanded from 72 to 100 medical beds and is located in the same building as the prior unit. In addition, a LabCorp patient service center will be co-located in the CRU, at which patients will have an opportunity to learn more about volunteering and participating in early-stage clinical trials.
Albany Molecular Research (AMRI), a global contract research and manufacturing organization based in Albany, N.Y., has acquired all the outstanding shares of Gadea Pharmaceutical Group, a privately held company located in Valladolid, Spain, specializing in technically complex active pharmaceutical ingredients (APIs) and finished drug product. The purchase price was $174 million, including the issuance of 2.2 million shares of common stock to Gadea’s owners, valued at $43.8 million, with the balance paid in cash and through the assumption of existing debt.
Epic Sciences, a San Diego, Calif.-based developer of novel diagnostics to personalize and advance the treatment and management of cancer, has inked an agreement with Laboratory Corporation of America Holdings (LabCorp), a Burlington, N.C.-based healthcare diagnostics company, to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development.